Replies to post #1799 on Cara Therapeutics Inc (CARA)

[hogar]

Don't look like purchases to me.

[JFBroderick]

Expected 2018 Milestones

Completion of enrollment and top-line data from the adaptive Phase 2/3 trial of I.V. CR845/difelikefalin for the treatment of acute post-operative pain.

Initiation of a placebo-controlled Phase 2 trial of Oral KORSUVA in patients with stage III-V CKD who are not on dialysis.

Initiation of an international Phase 3 trial of KORSUVA injection in hemodialysis patients with CKD-aP.

Initiation of Phase 2 trial of Oral KORSUVA in patients with CLD-aP.
Upcoming Activities:


The Company expects to make presentations at the following medical conferences through May, 2018:

National Kidney Foundation Spring Clinical Meeting, April 10-14, 2018

American Academy of Pain Medicine’s Annual Meeting, April 26-29, 2018

International Investigative Dermatology Meeting, May 16-19, 2018